In conclusion, our study contributes to the current understanding of the beneficial effects of SGLT2 inhibitors, and it specifically demonstrates that this therapy reduces maladaptive repair and CKD development, even when it is administered for only a short period after AKI has occurred. This evidence concerns the gene SLC5A2 and acute kidney injury.